{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:01:47Z","timestamp":1784854907606,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CD112 emerges as a novel immune checkpoint (IC) in various malignancies, its spatial biology and dual mechanisms in cervical cancer (CC) progression are unexplored. This study systematically analyzes the dual-functions of CD112 in immune evasion and metabolic adaptation in CC. Proteomics and immune checkpoint analysis were performed on 10 CC and normal tissues to explore key targets. Multiplex immunofluorescence (mIHC) on 318 CC tissue microarrays analyzed CD112\/CD112R spatial distribution and prognosis. Tumor cell and T cell co-culture models and immunocompetent murine models were used to validate effects of anti-CD112 mAb\u00b1anti-PD-1 treatment. CD112 expression in the infiltrated and margine areas correlated with PD-1\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells density (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.545,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), predicting unfavorable prognosis. Functional studies show that CD112 on tumor cells interacts with CD112R on CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, promoting abnormal numbers and functions of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, while CD112 antibodies can reverse CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell exhaustion and enhance the anti-tumor effects by synergized with PD-1 inhibitors. Mechanistically, the transcription factor Sp1 drives the overexpression of CD112 in CC cells. Additionally, CD112 confers resistance to ferroptosis in CC through the SLC7A11\/GPX4 pathway. CD112 acts as a \u201cdual-target\u201d mediating immune suppression and ferroptosis resistance. Combining CD112 and PD-1 inhibition may enhance CC immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08902-y","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:56:13Z","timestamp":1779890173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatiotemporal mapping of CD112 unveils its dichotomous role in T-cell exhaustion and ferroptosis crosstalk in cervical cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Lihua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-6850","authenticated-orcid":false,"given":"Yuxuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-713X","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-8215","authenticated-orcid":false,"given":"Weidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duancheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"8902_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8902_CR2","unstructured":"Chyong-Huey Lai, Jeffrey C Goh, Efren J Domingo, Jae Hoon Kim, Peng Peng, Vince Grillo, et al. Treatment patterns and disparities in locally advanced cervical cancer: insights from the Asia Pacific Region. ASGO. 2023."},{"key":"8902_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14737140.2021.1879646","volume":"21","author":"C Gennigens","year":"2021","unstructured":"Gennigens C, De Cuypere M, Hermesse J, Kridelka F, Jerusalem G. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther. 2021;21:657\u201371.","journal-title":"Expert Rev Anticancer Ther"},{"key":"8902_CR4","doi-asserted-by":"crossref","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802\u201312.","DOI":"10.1200\/JCO.2008.16.4368"},{"key":"8902_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023\u201375.","journal-title":"Lancet"},{"key":"8902_CR6","doi-asserted-by":"crossref","unstructured":"Ott PA, Dotti G, Yee C, Goff SL. An update on adoptive T-cell therapy and neoantigen vaccines. Am Soc Clin Oncol Educ Book. 2019;39:e70\u20138.","DOI":"10.1200\/EDBK_238001"},{"key":"8902_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801.","journal-title":"Nat Commun"},{"key":"8902_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"8902_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"H Chung","year":"2019","unstructured":"Chung H, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37:1470\u20138.","journal-title":"J Clin Oncol"},{"key":"8902_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856\u201367.","journal-title":"N Engl J Med"},{"key":"8902_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","volume":"21","author":"NR Abu-Rustum","year":"2023","unstructured":"Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN guidelines\u00ae insights: cervical cancer, version 1. 2024 J Natl Compr Canc Netw. 2023;21:1224\u201333.","journal-title":"2024 J Natl Compr Canc Netw"},{"key":"8902_CR12","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","volume":"37","author":"H Stamm","year":"2018","unstructured":"Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37:5269\u201380.","journal-title":"Oncogene"},{"key":"8902_CR13","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/cas.13992","volume":"110","author":"I Bekes","year":"2019","unstructured":"Bekes I, L\u00f6b S, Holzheu I, Janni W, Baumann L, W\u00f6ckel A, et al. Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role? Cancer Sci. 2019;110:1872\u201382.","journal-title":"Cancer Sci"},{"key":"8902_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/bs.ctdb.2014.11.019","volume":"112","author":"K Mandai","year":"2015","unstructured":"Mandai K, Rikitake Y, Mori M, Takai Y. Nectins and nectin-like molecules in development and disease. Curr Top Dev Biol. 2015;112:197\u2013231.","journal-title":"Curr Top Dev Biol"},{"key":"8902_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Ku\u010dan Brli\u0107","year":"2019","unstructured":"Ku\u010dan Brli\u0107 P, Lenac Rovi\u0161 T, Cinamon G, Tsukerman P, Mandelboim O, Jonji\u0107 S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16:40\u201352.","journal-title":"Cell Mol Immunol"},{"key":"8902_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","volume":"54","author":"HS Jin","year":"2021","unstructured":"Jin HS, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54:2\u201311.","journal-title":"BMB Rep"},{"key":"8902_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1084\/jem.20150785","volume":"213","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, et al. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016;213:167\u201376.","journal-title":"J Exp Med"},{"key":"8902_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/2326-6066.CIR-18-0442","volume":"7","author":"S Whelan","year":"2019","unstructured":"Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, et al. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunol Res. 2019;7:257\u201368.","journal-title":"Cancer Immunol Res"},{"key":"8902_CR19","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45:1892\u2013905.","journal-title":"Eur J Immunol"},{"key":"8902_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1158\/2326-6066.CIR-18-0460","volume":"7","author":"B Murter","year":"2019","unstructured":"Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R, et al. Mouse PVRIG has CD8+ T cell-specific coinhibitory functions and dampens antitumor immunity. Cancer Immunol Res. 2019;7:244\u201356.","journal-title":"Cancer Immunol Res"},{"key":"8902_CR21","doi-asserted-by":"publisher","first-page":"350.","DOI":"10.1038\/s41467-024-55700-1","volume":"16","author":"R Santos Peixoto","year":"2025","unstructured":"Santos Peixoto R, Miller BF, Brusko MA, Aihara G, Atta L, Anant M, et al. Characterizing cell-type spatial relationships across length scales in spatially resolved omics data. Nat Commun. 2025;16:350.","journal-title":"Nat Commun"},{"key":"8902_CR22","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180\u201391.","journal-title":"Nat Cell Biol"},{"key":"8902_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102703","volume":"62","author":"D Cheff","year":"2023","unstructured":"Cheff D, Huang C, Scholzen K, Gencheva R, Ronzetti M, Cheng Q, et al. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1. Redox Biol. 2023;62:102703.","journal-title":"Redox Biol"},{"key":"8902_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.crimmu.2022.05.003","volume":"3","author":"L Lu","year":"2022","unstructured":"Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, et al. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immunol. 2022;3:118\u201327.","journal-title":"Curr Res Immunol"},{"key":"8902_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24010-1","volume":"12","author":"DW Ho","year":"2021","unstructured":"Ho DW, Tsui Y, Chan L, Sze KM, Zhang X, Cheu J, et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021;12:3684.","journal-title":"Nat Commun"},{"key":"8902_CR26","first-page":"179","volume":"6","author":"X Miao","year":"2013","unstructured":"Miao X, Yang Z, Xiong L, Zou Q, Yuan Y, Li J, et al. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell\/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int J Clin Exp Pathol. 2013;6:179\u201390. Epub 2013 Jan 15.","journal-title":"Int J Clin Exp Pathol"},{"key":"8902_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pro.2628","volume":"24","author":"Y Fujiwara","year":"2015","unstructured":"Fujiwara Y, Goda N, Tamashiro T, Narita H, Satomura K, Tenno T, et al. Crystal structure of afadin PDZ domain-nectin-3 complex shows the structural plasticity of the ligand-binding site. Protein Sci. 2015;24:376\u201385.","journal-title":"Protein Sci"},{"key":"8902_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/glia.23578","volume":"67","author":"X Meng","year":"2019","unstructured":"Meng X, Maurel P, Lam I, Heffernan C, Stiffler MA, McBeath G, et al. Necl-4\/Cadm4 recruits Par-3 to the Schwann cell adaxonal membrane. Glia. 2019;67:884\u201395.","journal-title":"Glia"},{"key":"8902_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm3802","volume":"15","author":"M Takeichi","year":"2014","unstructured":"Takeichi M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. Nat Rev Mol Cell Biol. 2014;15:397\u2013410.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8902_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1083\/jcb.200103113","volume":"156","author":"A Mizoguchi","year":"2002","unstructured":"Mizoguchi A, Nakanishi H, Kimura K, Matsubara K, Ozaki-Kuroda K, Katata T, et al. Nectin: an adhesion molecule involved in formation of synapses. J Cell Biol. 2002;156:555\u201365.","journal-title":"J Cell Biol"},{"key":"8902_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nature24637","volume":"551","author":"SW Alvarez","year":"2017","unstructured":"Alvarez SW, Sviderskiy VO, Terzi EM, Papagiannakopoulos T, Moreira AL, Adams S, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature. 2017;551:639\u201343.","journal-title":"Nature"},{"key":"8902_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.canlet.2014.11.014","volume":"356","author":"C Louandre","year":"2015","unstructured":"Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015;356:971\u20137.","journal-title":"Cancer Lett"},{"key":"8902_CR33","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1172\/JCI99032","volume":"128","author":"B Hassannia","year":"2018","unstructured":"Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest. 2018;128:3341\u201355.","journal-title":"J Clin Invest"},{"key":"8902_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119845","volume":"240","author":"X Sun","year":"2020","unstructured":"Sun X, Cao Z, Mao K, Wu C, Chen H, Wang J, et al. Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib. Biomaterials. 2020;240:119845.","journal-title":"Biomaterials"},{"key":"8902_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.celrep.2017.12.077","volume":"22","author":"A Tarangelo","year":"2018","unstructured":"Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 2018;22:569\u201375.","journal-title":"Cell Rep"},{"key":"8902_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/14728222.2014.914173","volume":"18","author":"S Safe","year":"2014","unstructured":"Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets. 2014;18:759\u201369.","journal-title":"Expert Opin Ther Targets"},{"key":"8902_CR37","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1158\/0008-5472.CAN-09-4161","volume":"70","author":"R Lin","year":"2010","unstructured":"Lin R, Wu C, Chang J, Juan L, Hsu H, Chen C, et al. Dysregulation of p53\/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 2010;70:5807\u201317.","journal-title":"Cancer Res"},{"key":"8902_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/cancers11010101","volume":"11","author":"E Monteleone","year":"2019","unstructured":"Monteleone E, Orecchia V, Corrieri P, Schiavone D, Avalle L, Moiso E, et al. SP1 and STAT3 functionally synergize to induce the RhoU small GTPase and a subclass of non-canonical WNT responsive genes correlating with poor prognosis in breast cancer. Cancers. 2019;11:101.","journal-title":"Cancers"},{"key":"8902_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep07162","volume":"4","author":"E Choi","year":"2014","unstructured":"Choi E, Nam J, Jung J, Cho N, Cho S. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014;4:7162.","journal-title":"Sci Rep"},{"key":"8902_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"8902_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/bfgp\/ely006","volume":"18","author":"Q He","year":"2019","unstructured":"He Q, Xu Y, Li J, Huang Z, Li X, Wang X. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genom. 2019;18:99\u2013106.","journal-title":"Brief Funct Genom"},{"key":"8902_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"8902_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41590-025-02352-y","volume":"27","author":"SL Park","year":"2026","unstructured":"Park SL, Painter MM, Manne S, Alcalde V, McLaughlin M, Sullivan MA, et al. Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and role in disease. Nat Immunol. 2026;27:110\u201325.","journal-title":"Nat Immunol"},{"key":"8902_CR44","doi-asserted-by":"publisher","first-page":"e008367","DOI":"10.1136\/jitc-2023-008367","volume":"12","author":"L Sun","year":"2024","unstructured":"Sun L, Ma Z, Zhao X, Tan X, Tu Y, Wang J, et al. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy. J Immunother Cancer. 2024;12:e008367.","journal-title":"J Immunother Cancer"},{"key":"8902_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-021-01112-3","volume":"14","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang Y, Cao G, Zheng X, Sun C, Wei H, et al. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. J Hematol Oncol. 2021;14:100.","journal-title":"J Hematol Oncol"},{"key":"8902_CR46","unstructured":"Surface Oncology\/GSK. First-time-in-human study of GSK4381562 in participants with advanced solid tumors. NCT05277051."},{"key":"8902_CR47","unstructured":"Junshi Biosciences. A study of JS009 monotherapy and triple combination in advanced malignancies. NCT05650203."},{"key":"8902_CR48","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","volume":"70","author":"K Hansen","year":"2021","unstructured":"Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng H, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021;70:3525\u201340.","journal-title":"Cancer Immunol Immunother"},{"key":"8902_CR49","doi-asserted-by":"publisher","first-page":"12358","DOI":"10.3390\/ijms232012358","volume":"23","author":"Y Sim","year":"2022","unstructured":"Sim Y, Um Y, Park J, Seo M, Park S. A novel antibody-drug conjugate targeting nectin-2 suppresses ovarian cancer progression in mouse xenograft models. Int J Mol Sci. 2022;23:12358.","journal-title":"Int J Mol Sci"},{"key":"8902_CR50","doi-asserted-by":"publisher","first-page":"e0196422","DOI":"10.1371\/journal.pone.0196422","volume":"13","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miyashita H, Ishimura Y, Ito Y, Tanaka Y, Hori A, et al. Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey. PLoS ONE. 2018;13:e0196422.","journal-title":"PLoS ONE"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08902-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:12:13Z","timestamp":1784851933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08902-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8902"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08902-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"655"}}